Comparison of ultrasound guided injection of botulinum toxin at the origin of plantar fasciitis with injection of botulinum toxin by Babcock method in the treatment of plantar fasciitis

开始日期2023-09-23

申办/合作机构

Shahid Beheshti University of Medical Sciences

JPRN-jRCT1090220265

/ RecruitingN/AIIT

The study for the effect of botulinum toxin for upper limb spasticity - The effect of botulinum toxin for upper limb spasticity

开始日期2016-11-24

申办/合作机构

Higuchi, Inc.

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的临床结果

登录后查看更多信息

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的转化医学

登录后查看更多信息

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的专利（医药）

登录后查看更多信息

1,690

项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Efficacy of isolated periocular botulinum toxin A injections versus periocular and adjunctive lower facial injections in hemifacial spasm: a randomized, controlled, noninferiority, crossover trial

Article

作者: Chirapapaisan, Niphon ; Rueangcharin, Phakinee ; Mukdar, Yanee ; Joradoln, Manassawee ; Rattanathamsakul, Natthapon ; Eiamsamarng, Akarawit ; Chuenkongkaew, Wanicha

PURPOSE:

To evaluate the necessity of botulinum toxin A (BoNT-A) administration in the lower face of patients with hemifacial spasm (HFS).

METHODS:

A randomized controlled non-inferiority crossover trial was conducted with 46 HFS patients (non-inferiority margin = 1). Patients were randomized (1:1) to receive either isolated periocular BoNT-A injections followed by conventional injections (periocular and lower face area) or the reverse sequence, with a 16-week washout. Primary outcomes were visual analog scale (VAS) for periocular and lower face regions at 4 weeks post injection. Secondary outcomes included the Hemifacial Spasm Grading Scale (HSGS), Samsung Medical Center grading system (SMC), HFS questionnaire (HFS-30), and adverse events. Trial registration: TCTR20220916002.

RESULTS:

Data from 43 patients were analyzed. Isolated periocular injections demonstrated non-inferiority to conventional injections. Periocular VAS was 0.488 ± 0.140 (isolated injections) and 0.279 ± 0.085 (conventional) , mean difference 0.209 (95% CI: 0.064, 0.354, p<0.01). Lower face VAS was 0.878 ± 0.167 and 0.582 ± 0.113, mean difference 0.295 (95% CI: 0.039, 0.552, p<0.01). No significant differences were noted in HSGS, SMC, or HFS-30 scores. Minor adverse events were observed in both techniques, while mouth drooping occured only with conventional injections.

CONCLUSION:

Isolated periocular injections resulted in slightly poorer symptom relief but did not exceed the non-inferiority margin, providing comparable efficacy to conventional injections in controlling HFS while using a lower total toxin dose and minimizing adverse effects.

2025-12-01·ANNALS OF MEDICINE

Research progress in the use of botulinum toxin type a for post-stroke spasticity rehabilitation: a narrative review.

Review

作者: Wang, Ya ; Guan, Yuanyuan ; Zhu, Zongjun ; Xiao, Hongbo ; Xu, Qianwen

BACKGROUND:

Stroke is a leading cause of long-term disability and death worldwide. Spasticity after stroke seriously affects patients' quality of life. If this state persists for a long time, it will lead to severe joint atrophy, reduced motor coordination, and even permanent disability. Therefore, clinical research has focused on the treatment of spasticity and the recovery of motor function after stroke.

AIM:

The aim of this paper is to explore the use of botulinum toxin type A in the rehabilitation of spasticity after stroke and to provide a theoretical basis for optimizing rehabilitation strategies, highlighting its potential value in reducing spasticity and improving motor function.

METHOD:

This article reviews the latest research progress on the application of BTX-A in spasticity after stroke, discusses the potential and challenges of BTX-A in reducing spasticity and improving motor function in patients with stroke.

RESULT:

Botulinum toxin type A (BTX-A) is a local muscle paralytic agent that has received extensive attention in recent years for its application in reducing muscle spasticity and promoting post-stroke rehabilitation.

CONCLUSION:

This article confirms that botulinum toxin type A has a significant clinical effect in treating muscle spasticity after stroke and also helps improve motor function restoration in patients. Studies have shown that botulinum toxin type A injections are effective in reducing spasticity and, when combined with rehabilitation training, can facilitate the recovery of motor function in post-stroke patients. Therefore, botulinum toxin type A has a broad application prospect in the rehabilitation of post-stroke spasticity.

2025-08-01·OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA

Nonsurgical Facial Esthetic Procedures

Review

作者: Desroches, Marie-Laure ; Deane, Emily C ; Moubayed, Sami P

Nonsurgical facial esthetic procedures have revolutionized cosmetic enhancement, offering minimally invasive options for facial rejuvenation. This comprehensive overview covers a wide range of techniques, including wrinkle relaxation with botulinum toxin, skin volumization using dermal fillers and biostimulators, hair restoration, and various skin tightening and texture improvement methods. The article details the mechanisms, applications, and potential risks of each procedure, highlighting recent advancements and trends in the field. It classifies these treatments into clinically-oriented categories based on patients' desired changes.

项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的新闻（医药）

2024-11-21

·Medical Design and Outsourcing

Merz Therapeutics and S3 Connected Health launch iFlexo

NEWS RELEASE: Merz Therapeutics and S3 Connected Health Pioneer New Digital Health Solution, iFlexo, for People Living with Post-Stroke Spasticity Dublin/Frankfurt — Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing rehabilitation for people with post-stroke spasticity as part of its ongoing commitment to supporting stroke survivors. The app, developed in collaboration with S3 Connected Health, provides targeted exercises and rehabilitation programs specifically aimed at improving mobility for those with mild to moderate spasticity. By offering guided routines, iFlexo aims to help stroke survivors regain independence and improve their overall quality of life. Merz Therapeutics is the first and only neurotoxins pharmaceutical company to offer a platform to support self-rehabilitation. iFlexo, developed and operated on S3 Connected Health’s digital health platform Affinial, was released in August 2024 and is available for iOS and Android in France. Developing iFlexo on Affinial enabled the creation of a differentiated user experience optimized for post-stroke patients. An accelerated time to market of just five months was achieved thanks to Affinial’s range of pre-built, customizable digital health services. The Affinial platform enables iFlexo to scale and evolve by addressing current and future compliance, legal, cybersecurity, and regulatory requirements. During the pilot stage in France, it gained significant interest from patients, clinicians, and key opinion leaders. Dr. Alexandre Bertholon, Physical Medicine & Rehabilitation at Le Clos Champirol, says: “iFlexo is a promising solution in physical rehabilitation, offering a much-needed response to the current challenges in the field. It enables patients to engage in self-rehabilitation at home, focusing on their personal goals. This platform not only supports patients but also enhances efficiency for healthcare professionals by optimizing and extending the results of rehabilitation. It demonstrates how new solutions can improve patient outcomes and make care more effective.” Up to one-third of stroke survivors experience spasticity, a condition that can severely limit their ability to perform everyday tasks, often leaving them reliant on others.[1] For these individuals, personalized botulinum neurotoxin injection therapy as part of a multimodal approach can improve muscle tone and consequently patient’s mobility and quality of life. [2] Merz Therapeutics and S3 Connected Health are committed to providing better outcomes for more patients and are currently working on expanding the solution to more countries, starting in the coming months. [1] Ali, A., McCarthy, A.D., Reeves, M. et al. Sheffield Adaptive Patterned Electrical Stimulation (SHAPES) Therapy for Post Stroke Arm spasticity: study protocol for a 3-arm, a partially blinded, randomised controlled trial. BMC Neurol 24, 437 (2024). [2] Otero-Luis I, Martinez-Rodrigo A, Cavero-Redondo I, Moreno-Herráiz N, Martínez-García I, Saz-Lara A. Effect of Botulinum Toxin Injections in the Treatment of Spasticity of Different Etiologies: An Umbrella Review. Pharmaceuticals. 2024; 17(3):310. Merz Therapeutics Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs. For more information, please visit: S3 Connected Health S3 Connected Health is the specialist digital health partner for life science companies, developing regulated digital health solutions that improve the lives of people with acute and chronic conditions. It has delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. The company’s scalable and secure solutions improve disease management, differentiate pharmaceutical products and deliver new therapeutic approaches. Affinial, S3 Connected Health’s digital health platform, offers partners the opportunity to develop customized digital health solutions tailored to specific patient, device or disease needs. The platform’s pre-built services provide best practice implementation to ensure successful solution adoption and an accelerated time-to-market. For more information, please visit: The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.

2024-05-21

·PRNewswire

Guidance for Common Post-stroke Condition of Spasticity Released by the American Academy of Physical Medicine and Rehabilitation

ROSEMONT, Ill., May 21, 2024 /PRNewswire/ -- The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has today released spasticity guidance to establish a framework that reviews treatment options, endorses the highest quality of evidence-based care, and encourages research where there are knowledge gaps. Spasticity is a group of symptoms characterized by muscle tightening or reduced stretchability following injuries to or conditions affecting the brain and spinal cord, including stroke, cerebral palsy, multiple sclerosis, traumatic brain injury, or spinal cord injuries. Continue Reading When spasticity symptoms are recognized early, physicians can better manage and treat it through a range of therapies. Post this Spasticity symptoms include uncontrollable rhythmic, shaking movements, cramping, spasms, and tight, rigid muscles that cannot be stretched easily and may cause pain. Other symptoms may include incoordination, fatigue, weakness, and impaired motor control. Spasticity is often delayed and an evolving condition. If left untreated, spasticity can cause muscles to become stuck, leading to joint deformity. "Physicians have a growing toolbox of treatments for spasticity," said guidance author Dr. Preeti Raghavan, MBBS. "When patients or their caregivers recognize the symptoms of spasticity and seek treatment for those symptoms, we have even better chances to manage and treat their spasticity symptoms through a range of therapies." The first line of treatment and management interventions aimed at reducing the effects of spasticity is rehabilitative therapy. Simple, non-pharmacologic interventions that facilitate movement and improve function should be attempted before resorting to treatments that carry more risks and side effects. Therapeutic interventions can be used individually or in combination, including oral medications, injectables such as Botulinum toxin, and surgical options. An integrated, multi-disciplinary, goal-centered management approach is essential to providing long-term, comprehensive care for spasticity. PM&R physicians are leaders in recovery and regularly care for patients with conditions that cause spasticity, such as rehabilitating patients post-stroke or other conditions causing spasticity. Because of this, PM&R physicians have the necessary specialized equipment, supplies, and prior authorization procedures in place to treat spasticity patients and work with their insurance providers. The guidance is published in the PM&R Journal. The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians specializing in physical medicine and rehabilitation. PM&R physicians, also known as physiatrists, treat a wide variety of medical conditions affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles and tendons. PM&R physicians evaluate and treat injuries, illnesses and disability and are experts in designing comprehensive, patient-centered treatment plans. Physiatrists utilize cutting-edge as well as time-tested treatments to maximize function and quality of life. SOURCE American Academy of Physical Medicine and Rehabilitation

2024-01-09

·PRNewswire

AMERICAN ACADEMY OF DERMATOLOGY: START THE NEW YEAR OFF WITH A FRESH START (AND SKIN)

Advice from a board-certified dermatologist on seeking cosmetic treatments ROSEMONT, Ill., Jan. 9, 2024 /PRNewswire/ -- With a rise in both public accessibility and visibility, cosmetic treatments are more popular than ever. Whether your New Year's resolution is to improve your health or to look and feel your best, the most important thing to remember is that your results depend largely on the skills and knowledge of the person performing your treatment. "There is no one-size-fits-all or 'cookie cutter' approach to combat the signs of aging because aging looks different on everyone. On the flipside, there is no one cosmetic treatment to address all of these changes," said Lauren Fine, MD, FAAD, a board-certified dermatologist in Chicago. "The best cosmetic outcomes are often achieved with a comprehensive approach, starting with skincare at home, combined with other in-office treatments recommended by a board-certified dermatologist that is taking all of these factors into account when recommending a cosmetic treatment that is best for you." While over-the-counter options are available, they may not be able to provide the results that a cosmetic procedure can deliver. Common treatment options include botulinum toxin, fillers, and lasers. Botulinum toxin is used to diminish signs of aging, including frown lines between the eyebrows and crow's feet, as well as for hyperhidrosis (excessive sweating). Most people see results within 3 to 7 days and results can last about 3 to 4 months—even longer when treating excessive sweating. Fillers are also used to diminish signs of aging by restoring lost fullness to the face, lips, and hands, as well as to lessen scars and erase fine lines. Most fillers provide immediate results; however, they tend to be temporary and require repeat treatments. Lasers can treat a variety of concerns including stretch marks, scars, the removal of unwanted hair, and age spots. It is important to note that lasers cannot fully remove stretch marks or scars, but rather make them less noticeable. Multiple sessions are often necessary to see results when undergoing this form of treatment. Before undergoing any cosmetic procedure, Dr. Fine and the AAD recommend asking the following questions: What are the doctor's credentials and are they board-certified? Remember, dermatologists are physicians with extensive education, training, and experience in keeping the skin, hair, and nails healthy. How many of these particular cosmetic surgery procedures has the physician performed? The procedure should be one that the doctor performs regularly. Ask to see before-and-after photos of previous patients. What result can I expect and are there any risks? Because your results depend largely on the skill and experience of the person performing the procedure, it is important to select a board-certified physician. A dermatologist can tell you if the procedure will deliver the desired results, based on the condition of your skin as well as your age and health. If you have specific cosmetic concerns or questions about a particular treatment, the best place to start is with a board-certified dermatologist. "While some cosmetic procedures may look easy to perform, understanding how to safely treat patients and deliver the best desired result requires an in-depth medical knowledge of the skin," shared Dr. Fine. "In the age of social media and information overload, anyone can tout themselves as an expert. Going to a board-certified dermatologist for cosmetic treatments ensures that you will receive effective results from an expert with a deep understanding of the skin." If you're considering a cosmetic procedure, visit aad.org/findaderm to find a board-certified dermatologist in your area. More Information Cosmetic treatments Cosmetic treatment safety AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology

100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Botulinum toxin(UroGen Pharma Ltd.)	M03AX01	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
尿失禁	临床2期	以色列	UroGen Pharma Ltd.	2016-10-01
膀胱过度活动症	临床2期	以色列	UroGen Pharma Ltd.	2016-10-01
间质性膀胱炎	临床2期	-	Allergan UC	-
间质性膀胱炎	临床2期	-	UroGen Pharma Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EADV2023	N/A	-	44	Botulinum toxin	鏇膚憲膚選鏇獵範築遞(齋觸鹹鬱鑰壓艱壓製襯) = intense pain during ( 2 ) or after ( 3, transitory ) infiltration and transitory decrease in manual strength ( 3 ) 廠構鏇獵壓窪壓餘獵衊 (衊膚襯遞網壓鏇鏇蓋窪 ) 更多	积极	2023-10-11
MDS2022	N/A	面肌痉挛	7	Patients receiving Botulinum toxin Injections	餘廠構蓋觸範膚艱鬱艱(顧繭醖膚淵夢積觸餘糧) = 鑰艱淵憲範簾憲獵艱鏇齋顧觸範艱襯網範衊餘 (艱遞鏇壓顧鏇遞顧鹽醖 )	积极	2022-09-15
APAO2019	N/A	良性基础型眼睑痉挛	-	Botulinum Toxin 25 IU	顧遞鏇膚艱簾獵鬱築顧(醖範膚膚築艱範構壓鑰) = 獵鹽鏇蓋廠淵窪窪網觸糧積顧鹽鏇鏇夢鹽獵糧 (繭餘齋築餘艱壓鹽鹹糧 ) 更多	-	2019-03-06
PREEMPT (AAN2016)	临床3期	偏头痛	168	Onabotulinumtoxin A	夢餘網網艱築範鹹醖願(選蓋築鹹糧淵築鹹範餘) = 鏇築繭積鹽艱選製願簾鏇獵鑰蓋願觸觸範築夢 (簾積醖膚選壓壓蓋鹽構 )	-	2016-04-05
PREEMPT (AAN2016)	临床3期	偏头痛	168	Incobotulinumtoxin A	夢餘網網艱築範鹹醖願(選蓋築鹹糧淵築鹹範餘) = 簾膚鏇鬱範製夢網鬱蓋鏇獵鑰蓋願觸觸範築夢 (簾積醖膚選壓壓蓋鹽構 )	-	2016-04-05
AAN2014	N/A	肌肉痉挛一线	-	abobotulinumtoxinA	鬱構襯憲襯餘獵鏇鏇憲(夢積淵觸襯醖齋夢齋淵) = 壓製廠網範獵糧艱積蓋選齋願壓膚壓艱鏇廠選 (繭觸願夢夢憲艱艱蓋鑰 )	积极	2014-04-08
AAN2014	N/A	肌肉痉挛一线	-	onabotulinumtoxinA	鬱構襯憲襯餘獵鏇鏇憲(夢積淵觸襯醖齋夢齋淵) = 鏇憲觸簾鹽選餘遞鏇範選齋願壓膚壓艱鏇廠選 (繭觸願夢夢憲艱艱蓋鑰 )	积极	2014-04-08
ARVO2008	N/A	面肌痉挛	31	Botulinum toxin type A	憲糧淵膚顧獵襯遞鏇觸(淵遞衊選艱築願構襯齋) = 獵襯鏇糧獵壓糧餘艱製繭餘蓋鬱膚選觸選憲淵 (淵夢鹹觸餘糧膚膚網願 ) 更多	-	2008-05-01